Skip to content

Effects of an Amino-acid Supplement on Hepatic Lipid Metabolism

Effects of a Supplementation With Amino-acids on Hepatic Lipid Metabolism

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01119989
Acronym
AMINOFRUCT
Enrollment
9
Registered
2010-05-10
Start date
2010-05-31
Completion date
2011-12-31
Last updated
2018-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

hepatic fat content, hepatic de novo lipogenesis

Brief summary

10 healthy male volunteers will be studied after * a 6 day weight maintenance, balanced diet * a 6 days weight maintenance, balanced diet supplemented with 3 grams fructose/kg body weight/day * a 6 days weight maintenance, balanced diet supplemented with 3 grams fructose/kg body weight/day and 20g amino-acids per day At the end of each 6 days period, the following measurements will be obtained * intrahepatic lipids (1H-MRS) * metabolic effects of fructose ingestion (measurement of substrate oxidation, gluconeogenesis from fructose, palmitate synthesis from fructose, plasma VLDL-kinetics) This is a randomized, double blinded study

Interventions

DIETARY_SUPPLEMENTFructose+maltodextrin placebo
DIETARY_SUPPLEMENTamino-acid + fructose

Sponsors

University of Bern
CollaboratorOTHER
University of Lausanne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* age 18-30 years * sex: males * BMI between 19 and 25 kg/m2 * less than 3 30min- exercise session/week

Exclusion criteria

* smokers * alcohol consumption more than 50g/week * consumption of drugs * history of diabetes in first degree relatives * presence of ferro-magnetic prosthesis, cardiac pacemakers, or any contra-indication to NMR

Design outcomes

Primary

MeasureTime frame
intrahepatic lipidsafter 6 days on each controlled diet

Secondary

MeasureTime frame
13C palmitate synthesisafter 6 days on each controlled diet

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026